Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium / Respimat One Year Study in COPD.

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. At least 40 years old~3. Smoker or ex-smoker~4. Smoking history \> 10 pack-years~5. Forced Expiratory Volume in 1 Second (FEV1) \< 60% predicted~Exclusion Criteria:~1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure~2. History of asthma or allergic conditions.~3. Malignancy requiring treatment within past 5 years~4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis~5. Known active tuberculosis~6. Known hypersensitivity to anticholinergic drugs.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium (Type: OTHER): Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
- Placebo (Type: OTHER): Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)

Based on this trial design, predict the completion outcome and termination type (if applicable).